Logo of Percheron Therapeutics (ASX:PER)Latest Percheron Therapeutics (ASX:PER) News

Page 1
Page 1 of 3

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

Percheron lodges prospectus for 280 million options as funding risks remain in focus

Percheron Therapeutics has lodged a prospectus for up to 280 million options linked to its earlier $2.3 million placement, with the securities carrying a $0.01 exercise price and expiring in April 2028. The filing raises no meaningful cash on issue, but could provide up to $2.8 million if all options are later exercised while adding a potentially dilutive layer to the capital structure.
Victor Sage
4 Nov 2026

FDA Clears Percheron's HMBD-002 Trial in Relapsed AML

Percheron Therapeutics has received a US FDA Safe to Proceed letter for Vanderbilt Health to begin an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine. The early-stage study will target up to 20 patients with relapsed or refractory AML or AML with MDS.
Ada Torres
2 Nov 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

Percheron funds Vanderbilt AML trial as cash runway reaches 8.6 quarters

Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
20 Oct 2026

Market Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Small-cap shares produced another uneven week, led by a major fall in Corporate Travel Management and strong gains in energy, gas and takeover stocks.
Investors rewarded rising profits and new deals, but sold several companies despite promising project news.
Logan Eniac
5 Sept 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

$2.3 Million Placement Secures Funding for Percheron's AML Trial

Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.
Ada Torres
1 Sept 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Percheron Therapeutics Launches Vanderbilt-Led Trial for HMBD-002 in AML

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.
Ada Torres
28 Aug 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

Percheron Therapeutics narrows FY2026 loss, advances HMBD-002 oncology drug with phase II trial planned

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.
Ada Torres
19 Aug 2026